1. Indications and Usage for Tecentriq 1.1 Non-Small Cell Lung Cancer TECENTRIQ, as a single-agent, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA [see Clinical Studies (14.1)] non-small cell lung cancer (NSCLC) ...
The safety of TECENTRIQ HYBREZA for its approved NSCLC indications [see INDICATIONS AND USAGE] has been established in adequate and well-controlled studies of intravenous atezolizumab for the: adjuvant treatment (following tumor resection and platinum-based chemotherapy) in adult patients with stage II...
1. Indications and Usage for Tecentriq Hybreza 1.1 Non-Small Cell Lung Cancer TECENTRIQ HYBREZA, as monotherapy, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA [see Clinical Studies (14.1)] non-small cell lung cancer...
KEYTRUDA is indicated for use at an additional recommended dosage of 400 mg every 6 weeks for classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma in adults [see INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION]. This indication is approved under accelerated approval based on phar...